Logo

People in the News: Matt Posard

Apr 03, 2013
Premium

Matt Posard has joined the board of directors of Halozyme Therapeutics, a biopharmaceutical company. Posard is currently Illumina's senior vice president and general manager of translational and consumer genomics. He has worked for the San Diego-based array vendor since 2006, serving first as its vice president of global marketing and then later as vice president of global sales. Prior to joining Illumina, Posard held various marketing positions at Gen-Probe and Biosite.

Filed under

Microarrays & Multiplexing
microarrays
Illumina
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.